Frontlight ResearchEarly access
WithdrawnNo phase
Surgery Versus Stereotactic Body Radiation Therapy for Stage up to IA2 (T1a or T1b) Non-small Cell Lung Cancer
Key facts
- Who runs it
- Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
- Where
- Canada2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- 28 Jan 2018
- Ended
- Feb 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Anatomical Segmentectomy, Lobectomy or Bilobectomy
- Stereotactic Body Radiation Therapy
- Record updated
- 24 August 2021
- Why it stopped
- Accrual issues
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Patients aged 18-75
- Pathologically (histologically or cytologically) proven NSCLC
- Stage IA2 T1aN0M0 or T1bN0M0 only, fit for surgery; Tumor ≤ 2 cm (T1a or T1b according to AJCC, 8th ed.)
- Hilar or mediastinal lymph nodes ≤ 1 cm with no abnormal hilar or mediastinal uptake on PET scan are considered N0; Patients with hilar or mediastinal lymph nodes > 1 cm on CT scan or abnormal PET scan (including suspicious but non-diagnostic uptake) are eligible, provided directed tissue biopsies by EBUS or mediastinoscopy of all abnormally identified areas are negative for cancer; EBUS preferable; No regional or distant metastases
- Resectable disease and treatable by SBRT
- Peripherally located tumor; Primary tumor within or touching the zone of the proximal bronchial tree, defined as a volume of 2 cm in all directions around the proximal bronchial tree are excluded (carina, right and left main bronchi, right and left upper lobe bronchi, intermedius bronchus, right middle lobe bronchus, lingular bronchus, right and left lower lobe bronchi); No involvement of the central pleura and/or structures of the mediastinum
- Staging studies must be done within 8 weeks prior to study entry
- Patients must provide study specific informed consent prior to study entry
Who cannot take part
- Previously operated lung cancer
- Previous thoracic irradiation
- Severe pulmonary hypertension
- Severe cardiac, hepatic or renal insufficiency
- Severe peripheral vascular disease
- Severe cerebral or psychiatric pathologies
- Severe chronic heart disease
- Patients with a history of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer, or other solid tumors curatively treated with no evidence of disease for ≥ 5 years following the end of treatment and which, in the opinion of the treating physician, do not have a substantial risk of recurrence of the prior malignancy
- Pulmonary nodule manifested as pure ground-glass opacity
- Life expectancy < 6 months
- Pregnant or lactating woman
- Unwilling to have follow-up
- Central tumor where pneumonectomy might be considered
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The primary objective of this study is disease free survival rate at 5 years in stage IA2 (T1aN0M0 or T1bN0M0 only) non-small cell lung cancer (NSCLC) patients treated either by surgery or stereotactic body radiation therapy (SBRT).
The 2 groups in the trial
- SurgeryExisting treatment, for comparison
Patients that will undergo surgery (anatomical segmentectomy, lobectomy or bilobectomy) as primary lung cancer treatment
Treatment: Anatomical Segmentectomy, Lobectomy or Bilobectomy
- SBRT (Stereotactic Body Radiation Therapy)Existing treatment, for comparison
Patients that will undergo SBRT as primary lung cancer treatment
Treatment: Stereotactic Body Radiation Therapy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 24 August 2021